{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T16:50:29Z","timestamp":1781974229378,"version":"3.54.5"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007343","name":"Universit\u00e0 degli Studi di Brescia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007343","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-026-00785-6","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T09:06:26Z","timestamp":1772615186000},"page":"367-379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Challenges and Perspectives in Optimising the Treatment of Arterial Hypertension: Role of the Ramipril-Amlodipine-Hydrochlorothiazide Single-Pill Combination"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-9441","authenticated-orcid":false,"given":"Maria Lorenza","family":"Muiesan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2764-6779","authenticated-orcid":false,"given":"Aldo Pietro","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1238-872X","authenticated-orcid":false,"given":"Roberto","family":"Pontremoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9912-9482","authenticated-orcid":false,"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9642-8380","authenticated-orcid":false,"given":"Massimo","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"4","key":"785_CR1","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/jhh.2016.71","volume":"31","author":"G Tocci","year":"2017","unstructured":"Tocci G, Nati G, Cricelli C, Parretti D, Lapi F, Ferrucci A, et al. Prevalence and control of hypertension in the general practice in Italy: updated analysis of a large database. J Hum Hypertens. 2017;31(4):258\u201362. https:\/\/doi.org\/10.1038\/jhh.2016.71.","journal-title":"J Hum Hypertens"},{"issue":"4","key":"785_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40292-022-00519-4","volume":"29","author":"R Del Pinto","year":"2022","unstructured":"Del Pinto R, Grassi G, Muiesan ML, Borghi C, Carugo S, Cicero AFG, et al. World hypertension day 2021 in Italy: results of a nationwide survey. High Blood Press Cardiovasc Prev. 2022;29(4):353\u20139. https:\/\/doi.org\/10.1007\/s40292-022-00519-4.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"3","key":"785_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40292-024-00642-4","volume":"31","author":"R Del Pinto","year":"2024","unstructured":"Del Pinto R, Agabiti Rosei C, Borghi C, Cipollini F, Cottone S, De Giorgi GA, et al. May measure month 2022 in Italy: a focus on fixed-dose combination, therapeutic adherence, and medical inertia in a nationwide survey. High Blood Press Cardiovasc Prev. 2024;31(3):309\u201320. https:\/\/doi.org\/10.1007\/s40292-024-00642-4.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"4","key":"785_CR4","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/hypertensionaha.118.11308","volume":"72","author":"F Rea","year":"2018","unstructured":"Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension. 2018;72(4):846\u201353. https:\/\/doi.org\/10.1161\/hypertensionaha.118.11308.","journal-title":"Hypertension"},{"issue":"9","key":"785_CR5","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1097\/hjh.0000000000003215","volume":"40","author":"L Savar\u00e9","year":"2022","unstructured":"Savar\u00e9 L, Rea F, Corrao G, Mancia G. Use of initial and subsequent antihypertensive combination treatment in the last decade: analysis of a large Italian database. J Hypertens. 2022;40(9):1768\u201375. https:\/\/doi.org\/10.1097\/hjh.0000000000003215.","journal-title":"J Hypertens"},{"issue":"3","key":"785_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2165\/00003495-200262030-00003","volume":"62","author":"DA Sica","year":"2002","unstructured":"Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62(3):443\u201362. https:\/\/doi.org\/10.2165\/00003495-200262030-00003.","journal-title":"Drugs"},{"issue":"11","key":"785_CR7","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/j.1751-7176.2010.00360.x","volume":"12","author":"AH Gradman","year":"2010","unstructured":"Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich). 2010;12(11):869\u2013. https:\/\/doi.org\/10.1111\/j.1751-7176.2010.00360.x. 78.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"3","key":"785_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/hjh.0000000000003916","volume":"43","author":"G Simonyi","year":"2025","unstructured":"Simonyi G, Burnier M, Narkiewicz K, Rokszin G, Abonyi-T\u00f3th Z, Kov\u00e1cs G, et al. Effect of single-pill versus free equivalent combinations on persistence and major adverse cardiovascular events in hypertension: a real-world analysis. J Hypertens. 2025;43(3):405\u201312. https:\/\/doi.org\/10.1097\/hjh.0000000000003916.","journal-title":"J Hypertens"},{"issue":"5","key":"785_CR9","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/0300060516645004","volume":"44","author":"G Simonyi","year":"2016","unstructured":"Simonyi G, Ferenci T, Alf\u00f6ldi S, Farsang C. Ramipril\u2009+\u2009amlodipine and ramipril\u2009+\u2009hydrochlorothiazide fixed-dose combinations in relation to patient adherence. J Int Med Res. 2016;44(5):1087\u201391. https:\/\/doi.org\/10.1177\/0300060516645004.","journal-title":"J Int Med Res"},{"issue":"6","key":"785_CR10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1097\/HJH.0000000000004002","volume":"43","author":"A Coca","year":"2025","unstructured":"Coca A, Borghi C, Stergiou GS, Ly NF, Lee C, Tricotel A, et al. Long-term event rates, risk factors, and treatment pattern in 1.4 million individuals qualifying for dual blood pressure Lowering therapy. J Hypertens. 2025;43(6):993\u20131002. https:\/\/doi.org\/10.1097\/HJH.0000000000004002.","journal-title":"J Hypertens"},{"issue":"33","key":"785_CR11","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339.","journal-title":"Eur Heart J"},{"issue":"12","key":"785_CR12","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/hjh.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA). J Hypertens. 2023;41(12):1874\u20132071. https:\/\/doi.org\/10.1097\/hjh.0000000000003480.","journal-title":"J Hypertens"},{"key":"785_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2025.06.004","author":"M Rosas-Peralta","year":"2025","unstructured":"Rosas-Peralta M, Mancia G, Camafort M, Galv\u00e1n-Oseguera H, Ferrario CM, Alcocer L et al. Single pill combination therapy for hypertension: new evidence and new challenges: combination therapy for hypertension. Trends Cardiovasc Med. 2025. https:\/\/doi.org\/10.1016\/j.tcm.2025.06.004","journal-title":"Trends Cardiovasc Med"},{"issue":"38","key":"785_CR14","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912\u20134018. https:\/\/doi.org\/10.1093\/eurheartj\/ehae178.","journal-title":"Eur Heart J"},{"key":"785_CR15","doi-asserted-by":"publisher","unstructured":"Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al. AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation andmanagement of high blood pressure in adults: a Report of theAmerican College of Cardiology\/American Heart Association JointCommittee on Clinical Practice Guidelines. Circulation. 2025;152(11):e114\u2013e218. https:\/\/doi.org\/10.1161\/HYP.0000000000000249","DOI":"10.1161\/HYP.0000000000000249"},{"key":"785_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejim.2024.04.011","volume":"126","author":"A Coca","year":"2024","unstructured":"Coca A, Whelton SP, Camafort M, L\u00f3pez-L\u00f3pez JP, Yang E. Single-pill combination for treatment of hypertension: just a matter of practicality or is there a real clinical benefit? Eur J Intern Med. 2024;126:16\u201325. https:\/\/doi.org\/10.1016\/j.ejim.2024.04.011.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"785_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","volume":"122","author":"DS Wald","year":"2009","unstructured":"Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290\u2013300. https:\/\/doi.org\/10.1016\/j.amjmed.2008.09.038.","journal-title":"Am J Med"},{"key":"785_CR18","unstructured":"Chauhan M, Patel JB, Ahmad F. Ramipril StatPearls. Treasure Island: StatPearls Publishing LLC; 2025."},{"key":"785_CR19","unstructured":"Bulsara KG, Patel P, Cassagnol M, Amlodipine: StatPearls. Treasure Island: StatPearls Publishing LLC; 2025."},{"key":"785_CR20","unstructured":"Herman LL, Weber P, Bashir K, Hydrochlorothiazide. StatPearls. Treasure Island: StatPearls Publishing LLC; 2025."},{"key":"785_CR21","doi-asserted-by":"publisher","first-page":"660943","DOI":"10.3389\/fonc.2021.660943","volume":"11","author":"JA Carlos-Escalante","year":"2021","unstructured":"Carlos-Escalante JA, de Jes\u00fas-S\u00e1nchez M, Rivas-Castro A, Pichardo-Rojas PS, Arce C, Wegman-Ostrosky T. The use of antihypertensive drugs as coadjuvant therapy in cancer. Front Oncol. 2021;11:660943. https:\/\/doi.org\/10.3389\/fonc.2021.660943.","journal-title":"Front Oncol"},{"key":"785_CR22","doi-asserted-by":"publisher","unstructured":"Sica D. Calcium channel blocker-related periperal edema: Can it be resolved? J clin hypertens (Greenwich). 2003 5(4):291. https:\/\/doi.org\/10.1111\/j.1524-6175.2003.02402.x","DOI":"10.1111\/j.1524-6175.2003.02402.x"},{"issue":"3","key":"785_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0011-393X(00)88520-3","volume":"60","author":"R Fogari","year":"1999","unstructured":"Fogari R, Zoppi A, Mugellini A, Preti P, Banderali A, Salvetti A. Effects of amlodipine, Nifedipine GITS, and indomethacin on angiotensin-converting enzyme inhibitor-induced cough: a randomized, placebo-controlled, double-masked, crossover study. Curr Therapeutic Res. 1999.https:\/\/doi.org\/10.1016\/S0011-393X(00)88520-3.","journal-title":"Curr Therapeutic Res"},{"issue":"9","key":"785_CR24","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3949\/ccjm.86a.18024","volume":"86","author":"T Momoniat","year":"2019","unstructured":"Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and arbs: managing potassium and renal function. Cleve Clin J Med. 2019;86(9):601\u20137. https:\/\/doi.org\/10.3949\/ccjm.86a.18024.","journal-title":"Cleve Clin J Med"},{"issue":"1","key":"785_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1714\/4425.44225","volume":"26","author":"N Ferri","year":"2025","unstructured":"Ferri N, Corsini A. Farmacologia clinica Delle Terapie Di associazione Nella prevenzione e nel Trattamento Delle malattie cardiovascolari. G Ital Cardiol. 2025;26(1):6\u201316. https:\/\/doi.org\/10.1714\/4425.44225.","journal-title":"G Ital Cardiol"},{"issue":"6","key":"785_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2165\/00129784-200606060-00012","volume":"6","author":"VR Anderson","year":"2006","unstructured":"Anderson VR, Perry CM, Robinson DM. Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients. Am J Cardiovasc Drugs. 2006;6(6):417\u201332. https:\/\/doi.org\/10.2165\/00129784-200606060-00012.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"9","key":"785_CR27","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2165\/00003495-200969090-00008","volume":"69","author":"GM Keating","year":"2009","unstructured":"Keating GM. Losartan\/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Drugs. 2009;69(9):1239\u201365. https:\/\/doi.org\/10.2165\/00003495-200969090-00008.","journal-title":"Drugs"},{"issue":"2","key":"785_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2165\/11204420-000000000-00000","volume":"70","author":"MP Curran","year":"2010","unstructured":"Curran MP. Amlodipine\/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. Drugs. 2010;70(2):191\u2013213. https:\/\/doi.org\/10.2165\/11204420-000000000-00000.","journal-title":"Drugs"},{"issue":"8875","key":"785_CR29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/0140-6736(93)92693-N","volume":"342","author":"AIRE Study Investigators","year":"1993","unstructured":"AIRE Study Investigators. Effect of Ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The acute infarction Ramipril efficacy (AIRE) study investigators. Lancet. 1993;342(8875):821\u20138.https:\/\/doi.org\/10.1016\/0140-6736(93)92693-N.","journal-title":"Lancet"},{"issue":"9069","key":"785_CR30","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","volume":"349","author":"GISEN Group","year":"1997","unstructured":"GISEN Group. Randomised placebo-controlled trial of effect of Ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN group (Gruppo Italiano Di studi epidemiologici in Nefrologia). Lancet. 1997;349(9069):1857\u201363.https:\/\/doi.org\/10.1016\/S0140-6736(96)11445-8.","journal-title":"Lancet"},{"issue":"9200","key":"785_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","volume":"355","author":"HOPE Study Investigators","year":"2000","unstructured":"HOPE Study Investigators. Effects of Ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart outcomes prevention evaluation study investigators. Lancet. 2000;355(9200):253\u20139.https:\/\/doi.org\/10.1016\/S0140-6736(99)12323-7.","journal-title":"Lancet"},{"issue":"3","key":"785_CR32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/nejm200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145\u201353. https:\/\/doi.org\/10.1056\/nejm200001203420301.","journal-title":"N Engl J Med"},{"issue":"1","key":"785_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2165\/00003495-199039010-00009","volume":"39","author":"PA Todd","year":"1990","unstructured":"Todd PA, Benfield P, Ramipril. A review of its Pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs. 1990;39(1):110\u201335. https:\/\/doi.org\/10.2165\/00003495-199039010-00009.","journal-title":"Drugs"},{"issue":"3","key":"785_CR34","doi-asserted-by":"publisher","first-page":"440","DOI":"10.2165\/00003495-199549030-00008","volume":"49","author":"JE Frampton","year":"1995","unstructured":"Frampton JE, Peters DH. Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure. Drugs. 1995;49(3):440\u201366. https:\/\/doi.org\/10.2165\/00003495-199549030-00008.","journal-title":"Drugs"},{"issue":"9","key":"785_CR35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/clc.4960140908","volume":"14","author":"D McCarron","year":"1991","unstructured":"McCarron D. 24-hour blood pressure profiles in hypertensive patients administered Ramipril or placebo once daily: magnitude and duration of antihypertensive effects. Ramipril multicenter study group. Clin Cardiol. 1991;14(9):737\u201342. https:\/\/doi.org\/10.1002\/clc.4960140908.","journal-title":"Clin Cardiol"},{"issue":"1","key":"785_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/030006059101900105","volume":"19","author":"C Spieker","year":"1991","unstructured":"Spieker C, Zidek W, Vetter H, Rahn KH. Ambulatory 24-h blood pressure monitoring in essential hypertensives treated with the angiotensin-converting enzyme inhibitor Ramipril. J Int Med Res. 1991;19(1):39\u201343. . https:\/\/doi.org\/10.1177\/030006059101900105","journal-title":"J Int Med Res"},{"issue":"6","key":"785_CR37","doi-asserted-by":"publisher","first-page":"E28","DOI":"10.1161\/hy1101.099502","volume":"38","author":"P Svensson","year":"2001","unstructured":"Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of Ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension. 2001;38(6):E28\u201332. https:\/\/doi.org\/10.1161\/hy1101.099502.","journal-title":"Hypertension"},{"issue":"7","key":"785_CR38","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/sj.jhh.1002174","volume":"21","author":"D Goyal","year":"2007","unstructured":"Goyal D, Chong AY, Watson RL, Prasad N, Watson RD. Assessment of single versus twice daily dosing of Ramipril by ambulatory blood pressure monitoring in patients similar to those included in the HOPE study. J Hum Hypertens. 2007;21(7):525\u201330. https:\/\/doi.org\/10.1038\/sj.jhh.1002174.","journal-title":"J Hum Hypertens"},{"issue":"18","key":"785_CR39","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","volume":"292","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA Netw Open. 2004;292(18):2217\u201325. https:\/\/doi.org\/10.1001\/jama.292.18.2217.","journal-title":"JAMA Netw Open"},{"key":"785_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejim.2024.12.021","volume":"133","author":"E Olsen","year":"2025","unstructured":"Olsen E, Jamerson K, Schmieder RE, S\u00f8raas CL, Mariampillai JE, Mancia G, et al. Effects of Valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: the VALUE trial. Eur J Intern Med. 2025;133:55\u201363. https:\/\/doi.org\/10.1016\/j.ejim.2024.12.021.","journal-title":"Eur J Intern Med"},{"issue":"Suppl 1","key":"785_CR41","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1097\/00005344-199117001-00011","volume":"17","author":"J Varrone","year":"1991","unstructured":"Varrone J. The efficacy and safety of amlodipine in the treatment of mild and moderate essential hypertension in general practice. J Cardiovasc Pharmacol. 1991;17(Suppl 1):S30\u20133. https:\/\/doi.org\/10.1097\/00005344-199117001-00011.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"785_CR42","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.jash.2014.02.004","volume":"8","author":"JG Wang","year":"2014","unstructured":"Wang JG, Yan P, Jeffers BW. Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials. J Am Soc Hypertens. 2014;8(5):340\u20139. https:\/\/doi.org\/10.1016\/j.jash.2014.02.004.","journal-title":"J Am Soc Hypertens"},{"issue":"23","key":"785_CR43","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and Lipid-Lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288(23):2981\u201397. https:\/\/doi.org\/10.1001\/jama.288.23.2981.","journal-title":"JAMA"},{"issue":"5","key":"785_CR44","doi-asserted-by":"publisher","first-page":"Cd003824","DOI":"10.1002\/14651858.CD003824.pub2","volume":"2014","author":"VM Musini","year":"2014","unstructured":"Musini VM, Nazer M, Bassett K, Wright JM. Blood pressure-lowering efficacy of monotherapy with Thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;2014(5):Cd003824. https:\/\/doi.org\/10.1002\/14651858.CD003824.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"26","key":"785_CR45","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1056\/NEJMoa2212270","volume":"387","author":"A Ishani","year":"2022","unstructured":"Ishani A, Cushman WC, Leatherman SM, Lew RA, Woods P, Glassman PA, et al. Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events. N Engl J Med. 2022;387(26):2401\u201310. https:\/\/doi.org\/10.1056\/NEJMoa2212270.","journal-title":"N Engl J Med"},{"issue":"9","key":"785_CR46","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/j.clinthera.2008.09.008","volume":"30","author":"RD Miranda","year":"2008","unstructured":"Miranda RD, Mion D Jr., Rocha JC, Kohlmann O Jr., Gomes MA, Saraiva JF, et al. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine\/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine\/ramipril (ATAR) study. Clin Ther. 2008;30(9):1618\u201328. https:\/\/doi.org\/10.1016\/j.clinthera.2008.09.008.","journal-title":"Clin Ther"},{"issue":"10","key":"785_CR47","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.4103\/0366-6999.181959","volume":"129","author":"G Simonyi","year":"2016","unstructured":"Simonyi G. Benefits of fixed dose combination of ramipril\/amlodipine in hypertensive diabetic patients: a subgroup analysis of RAMONA trial. Chin Med J (Engl). 2016;129(10):1224\u20138. https:\/\/doi.org\/10.4103\/0366-6999.181959.","journal-title":"Chin Med J (Engl)"},{"issue":"23","key":"785_CR48","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","volume":"359","author":"K Jamerson","year":"2008","unstructured":"Jamerson K, Weber MA, Bakris GL, Dahl\u00f6f B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417\u201328. https:\/\/doi.org\/10.1056\/NEJMoa0806182.","journal-title":"N Engl J Med"},{"issue":"4","key":"785_CR49","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.numecd.2021.11.015","volume":"32","author":"C Borghi","year":"2022","unstructured":"Borghi C, Levy BI. Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis. Nutr Metab Cardiovasc Dis. 2022;32(4):815\u201326. https:\/\/doi.org\/10.1016\/j.numecd.2021.11.015.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"785_CR50","doi-asserted-by":"publisher","first-page":"e1921618","DOI":"10.1001\/jamanetworkopen.2019.21618","volume":"3","author":"J Wei","year":"2020","unstructured":"Wei J, Galaviz KI, Kowalski AJ, Magee MJ, Haw JS, Narayan KMV, et al. Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis. JAMA Netw Open. 2020;3(2):e1921618. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.21618.","journal-title":"JAMA Netw Open"},{"issue":"7404","key":"785_CR51","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427. https:\/\/doi.org\/10.1136\/bmj.326.7404.1427.","journal-title":"BMJ"},{"issue":"8","key":"785_CR52","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1517\/14656566.2012.683175","volume":"13","author":"R Fogari","year":"2012","unstructured":"Fogari R, Zoppi A, Mugellini A, Maffioli P, Preti P, Derosa G. Effects of Valsartan or Ramipril addition to amlodipine\/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. Expert Opin Pharmacother. 2012;13(8):1091\u20139. https:\/\/doi.org\/10.1517\/14656566.2012.683175.","journal-title":"Expert Opin Pharmacother"},{"key":"785_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10245921","author":"AFG Cicero","year":"2021","unstructured":"Cicero AFG, Fogacci F, Rizzoli E, D\u2019Addato S, Borghi C Long-term impact of different triple combination antihypertensive medications on blood pressure control, metabolic pattern and incident events: data from the Brisighella heart study. J Clin Med. 2021. . https:\/\/doi.org\/10.3390\/jcm10245921.","journal-title":"J Clin Med"},{"issue":"10022","key":"785_CR54","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/s0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure Lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957\u201367. https:\/\/doi.org\/10.1016\/s0140-6736(15)01225-8.","journal-title":"Lancet"},{"issue":"10285","key":"785_CR55","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625\u201336.https:\/\/doi.org\/10.1016\/S0140-6736(21)00590-0","journal-title":"Lancet"},{"issue":"12","key":"785_CR56","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2412006","volume":"392","author":"Y Bi","year":"2025","unstructured":"Bi Y, Li M, Liu Y, Li T, Lu J, Duan P, et al. Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med. 2025;392(12):1155\u201367. https:\/\/doi.org\/10.1056\/NEJMoa2412006.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"785_CR57","doi-asserted-by":"publisher","first-page":"S308","DOI":"10.2337\/dc11-s245","volume":"34","author":"E Grossman","year":"2011","unstructured":"Grossman E. Blood pressure: the lower, the better: the Con side. Diabetes Care. 2011;34(Suppl 2):S308\u201312. https:\/\/doi.org\/10.2337\/dc11-s245.","journal-title":"Diabetes Care"},{"issue":"11","key":"785_CR58","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/jch.13396","volume":"20","author":"F Viazzi","year":"2018","unstructured":"Viazzi F, Leoncini G, Grassi G, Pontremoli R. Antihypertensive treatment and renal protection: is there a J-curve relationship? J Clin Hypertens. 2018;20(11):1560\u201374. https:\/\/doi.org\/10.1111\/jch.13396.","journal-title":"J Clin Hypertens"},{"key":"785_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaf145","author":"M Volpe","year":"2025","unstructured":"Volpe M, Gallo G, Guzik TJ, Williams B, Messerli FH. Blood pressure management in secondary prevention after myocardial infarction. Cardiovasc Res. 2025. https:\/\/doi.org\/10.1093\/cvr\/cvaf145.","journal-title":"Cardiovasc Res"},{"issue":"10507","key":"785_CR60","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/s0140-6736(25)01391-1","volume":"406","author":"X Guo","year":"2025","unstructured":"Guo X, Sun G, Xu Y, Zhou S, Song Q, Li Y, et al. Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials. Lancet. 2025;406(10507):1009\u201319. https:\/\/doi.org\/10.1016\/s0140-6736(25)01391-1.","journal-title":"Lancet"},{"issue":"5","key":"785_CR61","doi-asserted-by":"publisher","first-page":"329","DOI":"10.7326\/m14-2803","volume":"163","author":"P Muntner","year":"2015","unstructured":"Muntner P, Whittle J, Lynch AI, Colantonio LD, Simpson LM, Einhorn PT, et al. Visit-to-visit variability of blood pressure and coronary heart disease, stroke, heart failure, and mortality: A cohort study. Ann Intern Med. 2015;163(5):329\u201338. https:\/\/doi.org\/10.7326\/m14-2803.","journal-title":"Ann Intern Med"},{"issue":"23","key":"785_CR62","doi-asserted-by":"publisher","first-page":"e036046","DOI":"10.1161\/jaha.124.036046","volume":"13","author":"J Heaton","year":"2024","unstructured":"Heaton J, Johal A, Alshami A, Okoh A, Udongwo N, Schoenfeld M, et al. Effect of combination antihypertensive pills on blood pressure control. J Am Heart Assoc. 2024;13(23):e036046. https:\/\/doi.org\/10.1161\/jaha.124.036046.","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"785_CR63","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/s0895-7061(03)00904-x","volume":"16","author":"S Julius","year":"2003","unstructured":"Julius S, Kjeldsen SE, Brunner H, Hansson L, Platt F, Ekman S, et al. VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens. 2003;16(7):544\u20138. https:\/\/doi.org\/10.1016\/s0895-7061(03)00904-x.","journal-title":"Am J Hypertens"},{"key":"785_CR64","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ijcard.2017.12.026","volume":"254","author":"M Volpe","year":"2018","unstructured":"Volpe M, Gallo G, Tocci G. Is early and fast blood pressure control important in hypertension management? Int J Cardiol. 2018;254:328\u201332. https:\/\/doi.org\/10.1016\/j.ijcard.2017.12.026.","journal-title":"Int J Cardiol"},{"key":"785_CR65","doi-asserted-by":"publisher","first-page":"h158","DOI":"10.1136\/bmj.h158","volume":"350","author":"W Xu","year":"2015","unstructured":"Xu W, Goldberg SI, Shubina M, Turchin A. Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension: population based retrospective cohort study. BMJ. 2015;350:h158. https:\/\/doi.org\/10.1136\/bmj.h158.","journal-title":"BMJ"},{"issue":"6","key":"785_CR66","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1161\/hypertensionaha.124.23508","volume":"82","author":"RB Barrett","year":"2025","unstructured":"Barrett RB, Riesser B, Martin B, Sachdev N, Rakotz MK, Sutherland SE, et al. Treatment in the first month after hypertension diagnosis improves blood pressure control. Hypertension. 2025;82(6):1129\u201336. https:\/\/doi.org\/10.1161\/hypertensionaha.124.23508.","journal-title":"Hypertension"},{"issue":"12","key":"785_CR67","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1002\/pds.4884","volume":"28","author":"K Marinier","year":"2019","unstructured":"Marinier K, Macouillard P, de Champvallins M, Deltour N, Poulter N, Mancia G. Effectiveness of two-drug therapy versus monotherapy as initial regimen in hypertension: a propensity score-matched cohort study in the UK clinical practice research datalink. Pharmacoepidemiol Drug Saf. 2019;28(12):1572\u201382. https:\/\/doi.org\/10.1002\/pds.4884.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"785_CR68","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1097\/hjh.0000000000002089","volume":"37","author":"A Salam","year":"2019","unstructured":"Salam A, Atkins ER, Hsu B, Webster R, Patel A, Rodgers A. Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37(8):1567\u201373. https:\/\/doi.org\/10.1097\/hjh.0000000000002089.","journal-title":"J Hypertens"},{"issue":"2","key":"785_CR69","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1161\/hypertensionaha.109.139816","volume":"55","author":"AK Gupta","year":"2010","unstructured":"Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399\u2013407. https:\/\/doi.org\/10.1161\/hypertensionaha.109.139816.","journal-title":"Hypertension"},{"issue":"5","key":"785_CR70","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/jch.13272","volume":"20","author":"LP Du","year":"2018","unstructured":"Du LP, Cheng ZW, Zhang YX, Li Y, Mei D. The impact of fixed-dose combination versus free-equivalent combination therapies on adherence for hypertension: a meta-analysis. J Clin Hypertens (Greenwich). 2018;20(5):902\u20137. https:\/\/doi.org\/10.1111\/jch.13272.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"6","key":"785_CR71","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/hypertensionaha.112.194167","volume":"59","author":"BM Egan","year":"2012","unstructured":"Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59(6):1124\u201331. https:\/\/doi.org\/10.1161\/hypertensionaha.112.194167.","journal-title":"Hypertension"},{"issue":"5","key":"785_CR72","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1161\/hypertensionaha.122.20810","volume":"80","author":"RE Schmieder","year":"2023","unstructured":"Schmieder RE, Wassmann S, Predel HG, Weisser B, Blettenberg J, Gillessen A, et al. Improved persistence to medication, decreased cardiovascular events and reduced all-cause mortality in hypertensive patients with use of single-pill combinations: results from the START-Study. Hypertension. 2023;80(5):1127\u201335. https:\/\/doi.org\/10.1161\/hypertensionaha.122.20810.","journal-title":"Hypertension"},{"issue":"10","key":"785_CR73","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1080\/03007995.2017.1367275","volume":"33","author":"LA Simons","year":"2017","unstructured":"Simons LA, Chung E, Ortiz M. Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and Perindopril for hypertension: Australian experience. Curr Med Res Opin. 2017;33(10):1783\u20137. https:\/\/doi.org\/10.1080\/03007995.2017.1367275.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"785_CR74","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1186\/s12889-024-19346-4","volume":"24","author":"G Morabito","year":"2024","unstructured":"Morabito G, Gregorio C, Ieva F, Barbati G, Mancia G, Corrao G, et al. Cost-effectiveness of single-pill and separate-pill administration of antihypertensive triple combination therapy: a population-based microsimulation study. BMC Public Health. 2024;24(1):1808. https:\/\/doi.org\/10.1186\/s12889-024-19346-4.","journal-title":"BMC Public Health"},{"issue":"6","key":"785_CR75","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1097\/hjh.0000000000002381","volume":"38","author":"K Tsioufis","year":"2020","unstructured":"Tsioufis K, Kreutz R, Sykara G, van Vugt J, Hassan T. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature. J Hypertens. 2020;38(6):1016\u201328. https:\/\/doi.org\/10.1097\/hjh.0000000000002381.","journal-title":"J Hypertens"},{"key":"785_CR76","doi-asserted-by":"publisher","DOI":"10.5646\/ch.2025.31.e25","author":"S Park","year":"2025","unstructured":"Park S, Shin E-S, Ihm S-H, Lee H-Y Optimizing systolic blood pressure targets for elderly hypertensive patients: a meta-analysis of mortality, cardiovascular outcomes, and adverse events. Clin Hypertens. 2025. https:\/\/doi.org\/10.5646\/ch.2025.31.e25.","journal-title":"Clin Hypertens"},{"issue":"11","key":"785_CR77","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1161\/hypertensionaha.124.23597","volume":"81","author":"PK Whelton","year":"2024","unstructured":"Whelton PK, O\u2019Connell S, Mills KT, He J. Optimal antihypertensive systolic blood pressure: a systematic review and meta-analysis. Hypertension. 2024;81(11):2329\u201339. https:\/\/doi.org\/10.1161\/hypertensionaha.124.23597.","journal-title":"Hypertension"},{"key":"785_CR78","doi-asserted-by":"publisher","first-page":"106409","DOI":"10.1016\/j.ejim.2025.07.005","volume":"142","author":"P Verdecchia","year":"2025","unstructured":"Verdecchia P, Angeli F, Reboldi G. Baseline risk and outcome benefit from intensive blood pressure targeting. a systematic review. Eur J Intern Med. 2025;142:106409. https:\/\/doi.org\/10.1016\/j.ejim.2025.07.005.","journal-title":"Eur J Intern Med"},{"issue":"5","key":"785_CR79","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40292-024-00670-0","volume":"31","author":"S Omboni","year":"2024","unstructured":"Omboni S, Bilo G, Saladini F, Di Guardo A, Palatini P, Parati G, et al. Standards for the implementation, analysis, interpretation, and reporting of 24-hour ambulatory blood pressure monitoring recommendations of the Italian society of hypertension. High Blood Press Cardiovasc Prev. 2024;31(5):425\u201336. https:\/\/doi.org\/10.1007\/s40292-024-00670-0.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"785_CR80","doi-asserted-by":"publisher","first-page":"e18527","DOI":"10.7717\/peerj.18527","volume":"12","author":"J Zeng","year":"2024","unstructured":"Zeng J, Gao Y, Hou C, Liu T. The impact of doctor-patient communication on medication adherence and blood pressure control in patients with hypertension: a systematic review. PeerJ. 2024;12:e18527. https:\/\/doi.org\/10.7717\/peerj.18527.","journal-title":"PeerJ"}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-026-00785-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-026-00785-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-026-00785-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T16:11:02Z","timestamp":1781971862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-026-00785-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":80,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["785"],"URL":"https:\/\/doi.org\/10.1007\/s40292-026-00785-6","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised for funding note added.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a review and does not contain any studies with human participants or animals performed by any of the authors. Therefore, ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This article does not contain any studies with human participants or animals performed by the authors. All cited studies are properly referenced and comply with ethical standards as reported by their respective authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Maria Lorenza Muiesan has received honoraria\/reimbursements for participation on advisory boards from Sandoz, AstraZeneca, Neopharmed Gentili, Novartis and Daiichi-Sankyo; and travel grants from Menarini Italy and Servier. Aldo P. Maggioni has received personal fees unrelated to the present work for participating in study committees sponsored by AstraZeneca, Novartis, Sanofi and Bayer; and honoraria for participation on an advisory board from Neopharmed Gentili. Roberto Pontremoli has received honoraria from AstraZeneca, Boehringer-Ingelheim, Lilly, MSD, Organon, Novartis, Menarini, Bayer, NovoNordisk, Vifor and Recordati. Alberto Corsini has received research funding and\/or honoraria from Amgen, Daiichi-Sankyo Europe, Amarin, DOC, MSD, Novartis, Recordati S.p.A., Sanofi and Viatris; and has received a grant from Sharper for writing a manuscript on combination therapy. Massimo Volpe has received honoraria for the speakers\u2019 bureaus or advisory boards from Menarini Int, Servier, Sandoz, AstraZeneca, Sanofi, Neopharmed Gentili and Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}